Trial Profile
Managing Neovascular Age-related Macular Degeneration (nAMD) Over 2 Years With a Treat and Extend (T&E) Regimen of 2 mg Intravitreal Aflibercept - a Randomized, Open-label, Active-controlled, Parallel-group Phase IV/IIIb Study (ARIES)
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 18 Jul 2022
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Polypoidal choroidal vasculopathy; Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms ARIES
- Sponsors Bayer; Bayer HealthCare
- 12 Jul 2022 Results of post-hoc analysis assessing the requirement for intravitreal aflibercept treatment intervals of <8 weeks in patients with neovascular age-related macular degeneration, and to assess vision and anatomic outcomes in such patients who require more intensive treatment, published in the Ophthalmology and Therapy.
- 18 Mar 2022 Results of post-hoc analysis assessing the relationship between the presence of intraretinal fluid (IRF) and subretinal fluid (SRF), both at baseline and throughout treatment, and best-corrected visual acuity (BCVA) in patients with neovascular age-related macular degeneration (nAMD) treated with intravitreal aflibercept, published in the Ophthalmology and Therapy.
- 23 Jan 2022 Results of a post hoc analysis describes outcomes in patients with treatment-naive nAMD receiving treat and extend intravitreal aflibercept for 104 weeks, who were identified as meeting criteria for an early hypothetical switch published in the Ophthalmology and Therapy